Trial · NCT07881367
Vitamin K2 (35) (MK-7) Reduces Dark Eye Circles: a Mechanistic and Human Efficacy Study
NCT07881367, Not applicable, Completed, Nanjing Ascend Biotech Technology Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Vitamin K2 (35) (MK-7) Reduces Dark Eye Circles: a Mechanistic and Human Efficacy Study. Trials, record NCT07881367. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07881367
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Vitamin K2 (35) (MK-7) Reduces Dark Eye Circles: a Mechanistic and Human Efficacy Study
- NCT number
- NCT07881367
- Status
- Completed
- Phases
- Not applicable
- Enrollment
- 34 participants, actual
- Lead sponsor
- Nanjing Ascend Biotech Technology Co., Ltd.
- Conditions
- Dark Eye Circles (Periorbital Hyperpigmentation)
- Interventions
- MK-7 Eye Cream, Placebo Eye Cream
- First posted
- 2026-10-19
- Last updated
- 2026-10-19
Source ClinicalTrials.gov
Registered outcomes4
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change in Individual Typology Angle (ITA°) of the under-eye area from baseline (T0) to Week 4 (T4w) | Baseline (T0) to Week 4 (T4w) | ITA° was derived from VISIA images analyzed using Image-Pro Plus software in the CIE Lab\* color space. Higher ITA° values indicate lighter skin complexion. The primary comparison was between the MK-7 Eye Cream-treated side and the Placebo Eye Cream-treated side at T4w. |
| Secondary | Change in L* value (lightness) of the under-eye area | Baseline (T0) to Week 2 (T2w) and Week 4 (T4w) | L\* was derived from VISIA images analyzed using Image-Pro Plus software in the CIE Lab\* color space. L\* ranges from 0 (black) to 100 (white), with higher values indicating brighter skin. Classified as a secondary, exploratory endpoint. |
| Secondary | Change in Melanin Index (MI) of the under-eye area | Baseline (T0) to Week 2 (T2w) and Week 4 (T4w) | MI was measured by Mexameter, a reflectance-based device. Higher values indicate greater pigmentation/darker tone in the epidermis. Classified as a secondary, exploratory endpoint. |
| Secondary | Change in Individual Typology Angle (ITA°) of the under-eye area at Week 2 | Baseline (T0) to Week 2 (T2w) | ITA° was derived from VISIA images analyzed using Image-Pro Plus software. The T2w assessment was a secondary, exploratory time point intended to characterize the onset of treatment effect. |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07881367
GET https://conductscience.org/api/trials/v1/NCT07881367/registered